No changing of the guard at Rideau Hall this summer
Article content
Andrew J. McLaughlin, a public affairs officer with the Canadian Armed Forces, confirmed that there will be no ceremonial foot guards conducting the ceremony at Rideau Hall as there have been in years past because of 'limited resources' of personnel.
Article content
Article content
Article content
The work of the ceremonial guard was temporarily disrupted during the early years of the COVID-19 pandemic, but resumed at a reduced capacity in 2023 and 2024 when the band, without parading soldiers, played on Parliament Hill. There were also ceremonial guards stationed outside Rideau Hall during those years.
Article content
'The Ceremonial Guard will conduct that changing of the guard parade on Parliament Hill but will not mount daily sentries at Rideau Hall for summer 2025,' McLaughlin said in an emailed statement.
Article content
The ceremony historically has taken place on Parliament Hill as well as a daily stationing of ceremonial guards on the grounds of Rideau Hall.
Article content
Article content
McLaughlin said that the changing of the guard parade will take place ever day at 10:00 a.m. on Parliament Hill until Aug. 20.
Article content
Article content
The full parade including band and soldiers will take place on Wednesdays to Sundays, while the band will perform without parading soldiers on Mondays and Tuesdays, McLaughlin added.
Article content
Article content
McLaughlin called the model a 'new and hybrid-type event structure' that will 'still provide the key aspects of this important historical ceremony to Canadians.'
Article content
The changing of the guard ceremony was first held on Parliament Hill in 1959 when Queen Elizabeth II visited Ottawa. Members of a regular Canadian army infantry conducted the ceremony. In the 1970s, the responsibility for the ceremony was given to two reservist regiments.
Article content
Since 2016, the ceremonial guard has been made up of both reservists and regular soldiers.
Article content
The Governor General's office acknowledged the importance of the tradition of the ceremonial guard at Rideau Hall, but referred questions about the changing of the guard to the Canadian Forces.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
a minute ago
- Winnipeg Free Press
A pause on higher tariffs for China is due to expire Tuesday. Here's what to know.
TAIPEI, Taiwan (AP) — A 90-day pause on imposing higher tariffs on China is due to expire on Tuesday and it is unclear if it will be extended. After the most recent round of China-U.S. trade talks, held late last month in Stockholm, Chinese and U.S. officials said they expected the deadline to be extended for another 90 days. The U.S. side said the decision was up to President Donald Trump. So far there has been no formal announcement about whether he will endorse an extension or push ahead with the higher tariffs. The uncertainty has left businesses in limbo and a decision to raise the import duties could jolt world markets. SILENCE FROM WASHINGTON AND BEIJING Trump has repeatedly shifted deadlines and tariff rates, and neither side has indicated what it plans for Tuesday. Extending the Aug. 12 deadline for reaching a trade agreement with China would forestall earlier threats of tariffs of up to 245%. Treasury Secretary Scott Bessent said Trump was deciding about another 90-day delay to allow time to work out details of an agreement setting tariffs on most products at 50%, including extra import duties related to illicit trade in the powerful opiate fentanyl. Higher tariffs are aimed at offsetting the huge, chronic U.S. trade deficit with China, which hit a 21-year low in July as the threat of tariffs bit into Chinese exports. It's not unusual for the U.S. to give hints on where talks stand, but it's rare for China to make announcements until major decisions are set. CHINA RESISTED CUTTING AN EARLY BARGAIN Prohibitively high tariffs on Chinese exports to the United States would put huge pressure on Beijing at a time when the Chinese economy, the world's second largest, is still recovering from a prolonged downturn in its property market. Lingering effects of the COVID-19 pandemic have left around 200 million of its workers reliant on 'gig work,' crimping the job market. Higher import taxes on small parcels from China have also hurt smaller factories and layoffs have accelerated, But the U.S. relies heavily on imports from China for all sorts of products, from household goods and clothing to wind turbines, basic computer chips, electric vehicle batteries and the rare earths needed to make them. That gives Beijing some powerful leverage in the negotiations with Washington. Even with higher tariffs, China remains competitive for many products. And its leaders are aware that the U.S. economy is only just beginning to feel the effects of higher prices from Trump's broad tariff hikes. For now, imports from China are subject to a 10% baseline tariff and a 20% extra tariff related to the fentanyl issue. Some products are taxed at higher rates. U.S. exports to China are subject to tariffs of around 30%. Before the two sides called a truce, Trump had threatened to impose 245% import duties on Chinese goods. China retaliated by saying it would hike its tariff on U.S. products to 125%. Monday Mornings The latest local business news and a lookahead to the coming week. MUCH IS AT STAKE A trade war between the world's two largest economies has ramifications across the global economy, affecting industrial supply chains, demand for commodities like copper and oil and geopolitical issues such as the war in Ukraine. After a phone call with Chinese leader Xi Jinping in June, Trump said he hoped to meet with Xi later this year. That's an incentive for striking a deal with Beijing. If the two sides fail to keep their truce, trade tensions could escalate and tariffs might rise to even higher levels, inflicting still more pain on both economies and rattling world markets. Businesses would refrain from making investment commitments and hiring, while inflation would surge higher. Companies are in an 'extended wait-and-see mode,' Oxford Economics said in a recent report.
CBC
32 minutes ago
- CBC
The Canadian army's long history of extremism
Last month, RCMP charged four people for their alleged involvement in a plot to forcibly take land north of Quebec city in what Mounties called an incident of "ideologically motivated violent extremism". Three of the men were denied bail last week. The accused, they charged, had planned to create an anti-government militia, but even more startling: two of the four people charged by RCMP are active members of the Canadian Armed Forces. While it's the first time an active member of the Canadian Armed Forces has faced terrorism-related charges, extremism in the military isn't new. Jonathan Montpetit, a senior Investigative Journalist with CBC News, chronicles the Forces' uneven track record on extremism, and how deeply this issue has infiltrated the ranks over the years.
Japan Forward
6 hours ago
- Japan Forward
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge
このページを 日本語 で読む United States President Donald Trump has stated plans to gradually increase tariffs on pharmaceuticals to as high as 250%. In response, Shionogi & Company, Limited President Isao Teshirogi announced on August 7 that the firm is considering building a new manufacturing plant in the US. The facility would produce Cefiderocol (brand name Fetroja), a drug for treating Gram-negative bacterial infections, which is in high demand in the US. Teshirogi revealed the plan in an interview with The Sankei Shimbun , adding that the plant is expected to be completed by January 2029, while Trump is still in office. Cefiderocol is currently produced exclusively at Shionogi's factory in Kanegasaki Town, Iwate Prefecture. If the plan goes ahead, the new facility would mark the company's first pharmaceutical manufacturing plant in the US. The firm is already evaluating the supply chain for the raw materials needed for construction, as well as securing land and personnel for the project. US President Donald Trump speaks at the White House, July 31, Washington (©Reuters via Kyodo) "If relying entirely on overseas pharmaceutical supplies poses a national security threat, then I agree," Teshirogi said, showing an understanding of Trump's policy. "I believe it's reasonable to want to accelerate and vigorously promote [domestic manufacturing]." "The ultimate goal is to save patients. If President Trump says, 'I want this product to be made in the US,' then we need to consider building a factory to meet that demand," he added. "We are already developing concrete plans for construction so we can act swiftly in line with the administration's direction." Regarding financing the project, Teshirogi said, "We will also require subsidies from the US government to support the construction of the new plant." Shionogi Pharmaceutical Research Center in Toyonaka City, Osaka (©Sankei by Yuta Yasumoto) The drug Cefiderocol is effective against infections caused by multidrug-resistant bacteria, meaning bacteria that have developed resistance to many other antibiotics. It's currently sold in Japan, the United States, and Europe, with demand growing, especially in the US. Drawing lessons from the COVID-19 pandemic, the Japanese pharmaceutical maker emphasizes the importance of promoting local production overseas to mitigate supply chain risks. "We are planning to launch Cefiderocol in the US around 2030 or 2040. If we do so, building a factory [there] is unavoidable," the company president said. However, specialized facilities are required to produce the antibiotics that become the raw materials for Cefiderocol. Manufacturing these antibiotics is complex, and there seem to be few of these facilities in the US. Therefore, securing skilled engineers could be challenging. Furthermore, China holds a near-monopoly on the supply of active ingredients for the antibiotics, "making it even more difficult to produce them at fermentation plants in the US," Teshirogi noted. Shionogi's president acknowledged that transferring manufacturing technology and securing a stable supply of raw materials would be the biggest hurdles ahead. Author: Yohei Ushijima, Sarasa Shimizu (The Sankei Shimbun) このページを 日本語 で読む
